Lung Cancer / Mesothelioma
As I mentioned in prior posts on the topic of second-line therapy, taxotere was the first treatment approved for second-line treatment of NSCLC. Back in 2000, first-line chemo with platinum-based doublets was becoming increasingly established as demonstrating a consistent survival benefit of several months for previously untreated patients with advanced NSCLC, and then a couple […]
15 CommentsChemotherapy after surgery has become increasingly well established as beneficial for many patients who have undergone surgery for early stage NSCLC, at least for stage II and IIIA resected disease (stage IB has had more mixed results and remains quite debatable). The chemo regimens that have been most clearly shown to confer improved survival […]
3 CommentsIn addition to risk for having a recurrence of a lung cancer that has been surgically removed, patients with a history of early NSCLC are also at risk for a second primary (unrelated to the first) lung cancer. In other words, having had a lung cancer, even if it was cured, means that a person remains […]
3 CommentsWell, as I suspected, the topic of lung cancer cancer screening has been a bit of a minefield, but I’m going to end now by trying to pull together where we are here and now, at least in the US. The article about the very impressive results of the I-ELCAP trial that was published in […]
7 CommentsThe topic of lung cancer screening is a very charged one, with most people, patients and physicians alike, having a strong opinion, either for or against. This is also an area in which there can be suspicion that any argument against screening is due to a financial calculation in which saving people from lung […]
17 CommentsThe issue of CT screening for lung cancer is a big one, and to handle it properly I’m going to write about it in a few installments. It’s also quite controversial, so today I’ll start with the reasons in favor of CT screening. Just by means of background, I’ll start by saying that chest […]
4 CommentsImmune-based approaches in lung cancer tend to generate significant buzz among patients and the general public, as well as in the media, but not as much optimism within the oncology world. Much of that is for good reason: while the concept of a minimally toxic, long-lasting anti-cancer approach like a vaccine is very appealing to […]
8 Comments Talking about statistics in lung cancer can be unpleasant, so it won’t hurt my feelings if you don’t want to read on. The numbers can be harsh.
This week, there was a good deal of fanfare about an annual article from the American Cancer Society on US cancer statistics (article is free, but I’ll […]
In contrast to the guidelines that exist for treating advanced lung cancer in the first-line setting for 4-6 cycles, there are really just practice patterns and good judgment to guide decisions of how long to treat in the second-line therapy. First, this is a relatively new question. As I previously mentioned when describing the […]
4 CommentsThe guidelines from the American Society for Clinical Oncology (ASCO) for NSCLC start the discussion on how long to continue first-line chemo as follows: “The optimal duration of chemotherapy remains a matter of debate.“ Just in case you thought it was only me saying that we don’t know the exact answer for one issue […]
8 Comments
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
